Incyte Gross Margin 2010-2024 | INCY

Incyte gross margin for the quarter ending September 30, 2024 was 92.81%.

  • Incyte average gross margin for 2023 was 93.29%, a 1.2% decline from 2022.
  • Incyte average gross margin for 2022 was 94.42%, a 0.56% decline from 2021.
  • Incyte average gross margin for 2021 was 94.95%, a 0.13% decline from 2020.

Gross margin can be defined as a company's total sales revenue minus its cost of goods sold, divided by the total sales revenue, expressed as a percentage.

Incyte Gross Margin 2010-2024 | INCY

  • Incyte average gross margin for 2023 was 93.29%, a 1.2% decline from 2022.
  • Incyte average gross margin for 2022 was 94.42%, a 0.56% decline from 2021.
  • Incyte average gross margin for 2021 was 94.95%, a 0.13% decline from 2020.

Gross margin can be defined as a company's total sales revenue minus its cost of goods sold, divided by the total sales revenue, expressed as a percentage.
Related Stocks
Company NameMarket
Cap
Amgen (AMGN)$173B
Vertex Pharmaceuticals (VRTX)$127.1B
Gilead Sciences (GILD)$114.2B
Bristol Myers Squibb (BMY)$112.1B
CSL (CSLLY)$91B
Regeneron Pharmaceuticals (REGN)$89.7B
GSK (GSK)$74.4B
Argenex SE (ARGX)$35.2B
Alnylam Pharmaceuticals (ALNY)$35.2B
Biogen (BIIB)$25.4B
BioNTech SE (BNTX)$25.4B
Illumina (ILMN)$24.2B
Moderna (MRNA)$19.9B
BeiGene (BGNE)$19.7B
Genmab (GMAB)$14.8B
Insmed (INSM)$13B
Vaxcyte (PCVX)$13B
BioMarin Pharmaceutical (BMRN)$12.6B
Sarepta Therapeutics (SRPT)$12.2B
Bio-Techne Corp (TECH)$12B
Exelixis (EXEL)$10.1B
Exact Sciences (EXAS)$10.1B
QIAGEN (QGEN)$10B
Revolution Medicines (RVMD)$9.9B
Intra-Cellular Therapies (ITCI)$9.5B
Bio-Rad Laboratories (BIO.B)$9.4B
Roivant Sciences (ROIV)$8.7B
Repligen (RGEN)$8.2B
Ascendis Pharma (ASND)$7.8B
Halozyme Therapeutics (HALO)$7.7B